These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24041364)

  • 21. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.
    Roberts M; Russell LB; Paltiel AD; Chambers M; McEwan P; Krahn M;
    Med Decis Making; 2012; 32(5):678-89. PubMed ID: 22990083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comments on the ISPOR Task Force Report on Translation and Adaptation of Outcomes Measures: guidelines and the need for more research.
    Lenderking WR
    Value Health; 2005; 8(2):92-3. PubMed ID: 15804317
    [No Abstract]   [Full Text] [Related]  

  • 27. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
    Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
    Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical Methods for the Analysis of Discrete-Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force.
    Prosser LA
    Value Health; 2016 Jun; 19(4):298-9. PubMed ID: 27325320
    [No Abstract]   [Full Text] [Related]  

  • 31. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
    Thokala P; Devlin N; Marsh K; Baltussen R; Boysen M; Kalo Z; Longrenn T; Mussen F; Peacock S; Watkins J; Ijzerman M
    Value Health; 2016 Jan; 19(1):1-13. PubMed ID: 26797229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Osgood ND; Padula WV; Higashi MK; Wong PK; Pasupathy KS; Crown W
    Value Health; 2015 Jan; 18(1):5-16. PubMed ID: 25595229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.
    Bridges JF; Hauber AB; Marshall D; Lloyd A; Prosser LA; Regier DA; Johnson FR; Mauskopf J
    Value Health; 2011 Jun; 14(4):403-13. PubMed ID: 21669364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Med Decis Making; 2012; 32(5):722-32. PubMed ID: 22990087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.
    Reed Johnson F; Lancsar E; Marshall D; Kilambi V; Mühlbacher A; Regier DA; Bresnahan BW; Kanninen B; Bridges JF
    Value Health; 2013; 16(1):3-13. PubMed ID: 23337210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
    Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
    Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report.
    Mandrik OL; Severens JLH; Bardach A; Ghabri S; Hamel C; Mathes T; Vale L; Wisløff T; Goldhaber-Fiebert JD
    Value Health; 2021 Apr; 24(4):463-472. PubMed ID: 33840423
    [No Abstract]   [Full Text] [Related]  

  • 40. Review: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Goettsch WG; Enzing J
    Value Health; 2014; 17(1):1-2. PubMed ID: 24438710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.